Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

14.70USD
14 Dec 2017
Change (% chg)

$-0.95 (-6.07%)
Prev Close
$15.65
Open
$15.65
Day's High
$15.70
Day's Low
$14.50
Volume
69,025
Avg. Vol
53,290
52-wk High
$15.95
52-wk Low
$5.50

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.00
Market Cap(Mil.): $371.72
Shares Outstanding(Mil.): 25.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

Oct 31 2017

BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln

* Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​ Source text: (http://bit.ly/2wFKm1k) Further company coverage:

Aug 08 2017

BRIEF-Stemline Therapeutics Q2 loss per share $0.66

* Stemline Therapeutics reports second quarter 2017 financial results

Aug 08 2017

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

Jun 23 2017

Competitors

Earnings vs. Estimates